What everyone forgets about good organisational change in pharma

Natasha Cowan, Daphne Chung|11th October 2018

When an organisation undergoes significant change, it can be make or break. On the one hand, if the company gets it wrong, it could end up with a toxic culture, high staff turnover rate and a loss of the company’s original mission – not to mention falling revenue.

On the other hand, when done well, an organisation could find itself better able to capture new opportunities, excite and galvanise employees and bring in new financial gains. If it fails to change at all, it could face a fate like that of Woolworths or Blockbuster – relegated to the history books.

In complex pharma markets there is often a greater need to be agile and reposition as the landscape transforms with the onset of new technology, diverse stakeholder relationships and competitor activities.

At some point, most companies will review the way they operate and find room for improvement. This could lead to small incremental changes or a full organisational transformation. Both require vision and sensitive execution, not to mention sparkling clarity in communications to stakeholders about why the change is taking place. However, these ‘softer’ steps are often overlooked, delaying the project and leading to higher costs.

Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account. 

What’s the top challenge pharma companies face when it comes to organisational transformation?

DC: We are in the thick of embracing digital opportunities to reach customers, shifting from product focus to customer focus As a result, multichannel is shaking up pharma companies to the core. They must examine how well they really understand their customers, their mechanisms for building and deriving value from customer insight, and their strengths and weaknesses in non-sales-rep channels.

At BLH, we talk a lot about People, Process and Platforms as key facets of organisational change, and multichannel transformation truly touches all three. There is a need for holistic assessment and strategic design of any multichannel transformation endeavour.

Do pharma marketers need to evolve their skills sets to keep up with changes like multichannel marketing?

They do, but to really gain buy-in, it’s important to build the appropriate communication and motivation. Often this proves challenging for our clients. Training doesn’t just convey new material, it should also support learners in embedding the information into their daily working lives. Marketers are subject to a regular onslaught of training and development in different, but only have 1% of the working week to focus on these opportunities. They need to know the real value and benefit and to be able to learn in an efficient and effective manner.

Launch Excellence 2020

Blue Latitude Health|18th November 2019

In this publication, we explore what makes a successful pharma launch from developing insight that drives behaviour change to lean launches and multi-indication launches, as well as an evaluation of the CAR-T market.

read more

Precision medicine at Blue Latitude Health

Blue Latitude Health|7th November 2019

At Blue Latitude Health we have identified 90+ insights about commercialising precision medicines. Check out our video to get a run down on three core components of the commercialisation and launch of precision medicines.

read more

Understanding the evolving CAR-T market

Ditte Funding, Maria Katsarou, Natasha Cowan|1st November 2019

In 2017 the approval of the first CAR-T treatment took the world by storm, transforming the way cancer is treated, but two years later more than 500 CAR-Ts are in development. So how can pharma ensure its product stands out from the crowd?

read more